Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Pasta

Showing results (161-170 of 162) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 162 results.
The Lancet. Respiratory Medicine|February 13, 2021
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension studyPatrick A Flume, Reta Fischer Biner, Damian G Downey, et al.
Annals of the American Thoracic Society|March 8, 2023
Lung Function Decline in Cystic Fibrosis: Impact of Data Availability and Modeling Strategies on Clinical InterpretationsRhonda Szczesniak, Eleni-Rosalina Andrinopoulou, Weiji Su, et al.
Pageof 17

Showing results (161-170 of 162) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 162 results.
The Lancet. Respiratory Medicine|February 13, 2021
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension studyPatrick A Flume, Reta Fischer Biner, Damian G Downey, et al.
Annals of the American Thoracic Society|March 8, 2023
Lung Function Decline in Cystic Fibrosis: Impact of Data Availability and Modeling Strategies on Clinical InterpretationsRhonda Szczesniak, Eleni-Rosalina Andrinopoulou, Weiji Su, et al.
Pageof 17